Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure
- 1 June 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 15 (3), 365-369
- https://doi.org/10.1097/hjr.0b013e3282f849d0
Abstract
Objective Anemia is a frequent comorbidity in chronic heart failure (CHF) adversely affecting patients’ prognosis. Erythropoietin seems to improve exercise capacity in CHF patients. This study investigates the effects of recombinant human erythropoietin analog darbepoetin-α on quality of life and emotional stress, evaluated by relevant questionnaires in patients with CHF and anemia. Methods Forty-one CHF patients [New York Heart Association class: II-III; left ventricular (LV) ejection fraction (EF) ≤40%; hemoglobin < 12.5 g/dl; serum creatinine < 2.5 mg/dl] were randomized (1:1) to receive either 3-month darbepoietin-α at 1.5 μg/Kg every 20 days plus iron orally (n = 21) or placebo plus iron orally (n = 20). Echocardiographic LVEF, questionnaires addressing quality of life (Kansas City Cardiomyopathy Questionnaire, functional and overall, Duke's Activity Status Index) and emotional stress [Zung self-rating depression scale (SDS), Beck Depression Inventory], as well as plasma b-type natriuretic peptide and 6-min walking distance (6MWT as a marker of exercise capacity) were assessed at baseline and posttreatment. Results A significant improvement in LVEF (32 ± 6 from 26 ± 6%, P < 0.001), 6MWT (274 ± 97 from 201 ± 113m, P < 0.01), hemoglobin (12.8 ± 1.4 from 10.9 ± 1.0 g/dl, P < 0.001) and plasma b-type natriuretic peptide (517 ± 579 from 829 ± 858 pg/ml, P = 0.002) was observed posttreatment only in darbepoetin-treated group. Kansas City Cardiomyopathy Questionnaire functional (78 ± 14 from 57 ± 24%, P < 0.01) and overall (68 ± 20 from 47 ± 22, P < 0.001), Duke's Activity Status Index (19 ± 11 from 14 ± 9, P < 0.05), Zung SDS (38 ± 10 from 47 ± 11, P < 0.05) and Beck Depression Inventory (11 ± 9 from 16 ± 10, P < 0.05) scores also improved in darbepoetin-treated patients, whereas they remain unchanged in the placebo group except for the Zung SDS which worsened (P≤0.05). A significant correlation between drug-induced percent changes in 6MWT and Zung SDS (r = –0.627, P < 0.05) was also observed. Conclusions Darbepoetin-α improves quality of life and emotional stress in CHF patients with anemia, with a parallel increase in exercise capacity.Keywords
This publication has 31 references indexed in Scilit:
- Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and AnemiaCirculation, 2008
- Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemiaEuropean Heart Journal, 2007
- Effect of Darbepoetin Alfa on Exercise Tolerance in Anemic Patients With Symptomatic Chronic Heart Failure: A Randomized, Double-Blind, Placebo-Controlled TrialJournal of the American College of Cardiology, 2007
- Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemiaAmerican Heart Journal, 2006
- Anemia in Chronic Heart FailureCirculation, 2006
- Anemia as a risk factor and therapeutic target in heart failureJournal of the American College of Cardiology, 2004
- Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart FailureCirculation, 2003
- Anemia Is Common in Heart Failure and Is Associated With Poor OutcomesCirculation, 2003
- The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled studyJournal of the American College of Cardiology, 2001
- The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizationsJournal of the American College of Cardiology, 2000